PRA Health Sciences has joined forces with a trial site group to focus on vaccine development, hoping to speed up patient recruitment and get more clinical studies rolling.
CRO Chiltern, in the process of integrating its latest acquisition, is focusing in on endocrinology and metabolism, broadening its expertise with an eye on diabetes R&D.
Contract drug developer Patheon is revamping its brand identity on the way to Wall Street, tinkering with its image ahead of a planned $100 million IPO.
Venn Life Sciences is expanding its reach across Europe, buying a small Dutch contractor to bolster its offerings in regulatory affairs.
Chinese contract drug developer ShangPharma is planning to invest $60 million to build a biologics research and manufacturing outpost near its home base in Shanghai.
German preclinical CRO NMI TT Pharmaservices is building a new branch at Bayer's new hub for biotech startups, hoping to expand the use of its discovery platform.
Covance, now a division of LabCorp, is planning to build a second manufacturing-enabled pharmacy adjacent to one of its clinical research sites, allowing the CRO to churn out doses of investigational drugs for ongoing studies.
The acquisitive BioClinica has picked up another service provider, buying a company specializing in safety monitoring and regulatory affairs to build out its offerings in drug development.
U.K. CRO Chiltern has wrapped up its acquisition of former U.S. competitor Theorem Clinical Research, expanding its payroll and global reach in the process.
PRA Health Sciences is building up its presence in Pennsylvania, adding 150 jobs with plans to dial up recruitment over the next two years.
CRO Accelovance is teaming up with a cancer-focused nonprofit to broaden its services in oncology trials, widening its net of expert investigators.
AMRI is brightening its expectations for 2015 after closing its latest buyout, counting on its manufacturing division to keep revenue rolling.
WuXi PharmaTech, making use of its recent $65 million investment in genomics, is teaming up with a Shanghai hospital to expand the scope of precision medicine in its home country.
German research outfit Evotec is dialing up its full-year revenue expectations thanks to a series of contract wins.
CRO Aragen Biosciences signed a deal with Dutch service provider ProteoNic Biotechnology to get its hands on a protein-production technology it believes can improve biologics development.
Private CRO Rho inked its largest-ever federal contract, signing a 7-year deal with the U.S. National Institutes of Health that will pay out about $16.5 million each year.
Hybrid R&D outfit Evotec signed a deal with Pfizer to collaborate on tissue fibrosis research, lending its expertise and discovery technology to the pharma giant in exchange for a cut of the benefits.
Swedish contract drugmaker Recipharm signed a deal with neighboring LobSor Pharmaceuticals to manufacture the company's new treatment for Parkinson's disease, all the while discussing a partnership with Novartis in the field of eye care.
CRO giant Icon is working with IBM in hopes of making clinical trials more efficient, tapping the company's famed Watson technology with an eye on speeding up recruitment and site selection.
Catalent watched as some unfavorable currency trends sapped its fiscal year revenue growth, but the company closed out its transformational year with a major increase in profits that management said is a sign of things to come.